CPRX - Catalyst Pharmaceuticals, Inc.
NEXT EARNINGS:
Feb 25, 2026
(today)
EPS Est: $0.42
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$33.00
DETAILS
HIGH:
$33.00
LOW:
$33.00
MEDIAN:
$33.00
CONSENSUS:
$33.00
UPSIDE:
36.42%
Market Cap:
2.97B
Volume:
1,298,134
Avg Volume:
1,239,195
52 Week Range:
19.05-26.58
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.73
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
181
IPO Date:
2006-11-08
EPS (TTM):
1.38
P/E Ratio:
15.08
Revenue (TTM):
491.73M
Total Assets:
851.41M
Total Debt:
3.19M
Cash & Equiv:
517.55M
Rev Growth (5Y):
36.9%
EPS Growth (5Y):
34.8%
FCF Growth (5Y):
47.2%
ROCE:
26.7%
Debt/Equity:
0.00
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-05 | $0.68 | $0.51 | +33.3% | $148.4M | $142.8M | +4.0% |
| 2025-08-06 | $0.68 | $0.58 | +17.2% | $146.6M | $140.4M | +4.4% |
| 2025-05-07 | $0.68 | $0.53 | +28.3% | $141.4M | $131.1M | +7.8% |
| 2025-02-26 | $0.70 | $0.32 | +118.7% | $141.8M | $134.2M | +5.7% |
| 2024-11-06 | $0.57 | $0.49 | +16.3% | $128.7M | $134.1M | -4.0% |
| 2024-08-07 | $0.56 | $0.42 | +33.3% | $122.7M | $111.9M | +9.7% |
| 2024-05-08 | $0.38 | $0.34 | +11.8% | $98.5M | $112.0M | -12.0% |
| 2024-02-28 | $0.53 | $0.48 | +10.4% | $110.6M | $110.6M | 0.0% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 491.73M | 398.20M | 214.20M | 140.83M | 119.07M | 102.31M | 500,000 | 0 | 0 | 0 | 0 | 0 |
| Net Income | 163.89M | 71.41M | 83.08M | 39.48M | 74.98M | 31.88M | (34.00M) | (18.41M) | (18.07M) | (20.23M) | (15.51M) | (12.15M) |
| EPS | 1.38 | 0.67 | 0.80 | 0.38 | 0.72 | 0.31 | -0.33 | -0.21 | -0.22 | -0.25 | -0.24 | -0.27 |
| Total Assets | 851.41M | 470.11M | 375.63M | 237.79M | 192.35M | 112.38M | 60.45M | 85.39M | 41.71M | 60.10M | 43.91M | 25.37M |
| Total Debt | 3.19M | 3.56M | 3.89M | 4.20M | 29,000 | 948,050 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash & Equivalents | 517.55M | 137.64M | 298.39M | 171.44M | 130.24M | 89.51M | 16.56M | 57.50M | 13.89M | 28.24M | 9.10M | 2.22M |
| Operating Cash Flow | 239.81M | 143.60M | 116.05M | 60.37M | 45.03M | 34.61M | (25.70M) | (13.74M) | (17.96M) | (18.02M) | (12.94M) | (9.88M) |
| Free Cash Flow | 239.25M | 61.86M | 116.02M | 59.35M | 45.02M | 34.59M | (25.80M) | (13.74M) | (18.06M) | (18.04M) | (13.00M) | (9.89M) |
| FCF per Share | 2.02 | 0.58 | 1.12 | 0.57 | 0.43 | 0.34 | -0.25 | -0.16 | -0.22 | -0.22 | -0.20 | -0.22 |
| Book Value | 727.63M | 387.88M | 300.42M | 206.83M | 169.60M | 87.63M | 50.78M | 80.96M | 39.31M | 55.48M | 35.24M | 21.39M |
| Cash & ST Investments | 517.55M | 137.64M | 298.39M | 191.27M | 140.28M | 94.52M | 53.48M | 84.01M | 40.41M | 58.40M | 39.28M | 23.71M |
| ROC Equity | 0.23 | 0.18 | 0.28 | 0.19 | 0.44 | 0.36 | -0.67 | -0.23 | -0.46 | -0.36 | -0.44 | -0.57 |